Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.39 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.37 |
| ▸ | MELK | Q14680 | 7/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21267028 | 0.84 | CDK2 (0.41) | HRH3 | |
| SCHEMBL24681513 | 0.84 | USP1 (0.42) | HRH3SUV39H2MELK | |
| SCHEMBL23425939 | 0.82 | HRH3 (0.45) | HRH3 | |
| SCHEMBL24061621 | 0.82 | MAPT (0.45) | HRH3 | |
| SCHEMBL21245679 | 0.81 | PIK3CA (0.40) | HRH3SUV39H2 | |
| SCHEMBL19145422 | 0.81 | MAPT (0.46) | HRH3 | |
| SCHEMBL19251500 | 0.79 | KDM4E (0.44) | HRH3SUV39H2 | |
| SCHEMBL21267710 | 0.79 | HRH3 (0.41) | HRH3SUV39H2MELK | |
| SCHEMBL23107223 | 0.78 | HRH3 (0.49) | HRH3 | |
| SCHEMBL23103856 | 0.78 | HRH3 (0.49) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | HRH3 1963/4885SUV39H2 673/4885MELK 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.